Creating the RIGHT Toxicology Strategy:
Learning from the Past to Shape the Future
Syngene Fireside Chat
In this 45-minute interactive virtual discussion on the topic ‘Creating the RIGHT toxicology strategy: Learning from the past to shape the future,’ we have Professor Ruth Roberts, Ph.D., ATS, FBTS, ERT, FRSB, FRCPath, Director and Co-founder, ApconiX; Alan Collis, Ph.D., Vice President, Integrated Drug Discovery Services, Syngene International Ltd; and host Chief Commercial Officer, Ashu Tandon, Syngene International Ltd.
The session will cover the following topics:
- Key trends in the toxicology space
- How Artificial Intelligence and in vitro studies co-exist and support an overarching tox strategy
- The evolution of In silico safety assessment and key trends for the future
- How to predict low frequency risks early on during the drug development process
Host for the session:
Ashu has 20 years of experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting, and outsourcing services in Research & Development. He has a successful track record of building multi-million dollar deals across multiple industry verticals and geographies.
As a member of Syngene’s Executive Committee, he plays an important role in driving strategy related to Commercial activities. Prior to joining Syngene, Ashu was with IQVIA (formerly QuintilesIMS), Infosys and Accenture.
Chief Commercial Officer,
Syngene International Ltd.
Panellists for the session:
Ruth is Director and Cofounder of ApconiX, an integrated ion channel and toxicology company, and also Chair and Director of Drug Discovery at the University of Birmingham. Prior to this, Ruth was Global Head of Regulatory Safety at AstraZeneca (2004-2014) and Director of Toxicology for Aventis (2002-2004). Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery, and drug development. With more than 140 publications in peer-reviewed journals, her work focuses on science-based approaches to drug discovery and development, especially in reducing attrition attributable to safety and toxicity. Ruth was the recipient of the S
OT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009, and the SOT Founders award in 2018 for outstanding leadership in toxicology.
Panellist: Professor Ruth Roberts,
Ph.D., ATS, FBTS, ERT, FRSB, FRCPath
Director and Co-founder,
Alan is a drug discovery and development scientist specializing in discovery, preclinical, and early clinical project leadership. Alan has served the European and US markets in various leadership roles, with responsibilities including medicinal chemistry, DMPK, safety assessment, CMC, and phase I studies. He has led 33 novel small molecules into preclinical evaluation by partnering with a diverse set of teams (internal and external) that initiated multiple clinical studies of new science. His prior experience includes working with Forma Therapeutics and Novartis.
Prior to joining Syngene, Alan was the Senior Vice President of Preclinical Development at Nimbus Therapeutics. Earlier in his career, Alan held significant leadership roles in medicinal chemistry in large pharma companies such as Aventis, Rhone-Poulenc Rorer, and Pfizer.
Panellist: Alan Collis, Ph.D.,
Vice President, Integrated Drug Discovery Services,
Syngene International Ltd.